Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(50.0%)
Phase 1
1(50.0%)
2Total
Phase 2(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01301573Terminated

Long Term Follow-Up Study for rAAV-GAD Treated Subjects

Role: lead

NCT00643890Phase 2Terminated

Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease

Role: lead

NCT00195143Phase 1Completed

Safety Study of Subthalamic Nucleus Gene Therapy for Parkinson's Disease

Role: lead

All 3 trials loaded